Advertisement
Canada markets close in 4 hours 41 minutes
  • S&P/TSX

    21,870.23
    -141.49 (-0.64%)
     
  • S&P 500

    5,058.41
    -12.14 (-0.24%)
     
  • DOW

    38,351.92
    -151.77 (-0.39%)
     
  • CAD/USD

    0.7288
    -0.0033 (-0.45%)
     
  • CRUDE OIL

    82.59
    -0.77 (-0.92%)
     
  • Bitcoin CAD

    89,280.65
    -2,196.02 (-2.40%)
     
  • CMC Crypto 200

    1,407.94
    -16.16 (-1.13%)
     
  • GOLD FUTURES

    2,346.80
    +4.70 (+0.20%)
     
  • RUSSELL 2000

    1,991.27
    -11.37 (-0.57%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ

    15,707.09
    +10.45 (+0.07%)
     
  • VOLATILITY

    16.07
    +0.38 (+2.42%)
     
  • FTSE

    8,037.49
    -7.32 (-0.09%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6816
    -0.0020 (-0.29%)
     

Why Shares of Provention Bio Went Up 30.3% in November

Why Shares of Provention Bio Went Up 30.3% in November

Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence. The pharmaceutical company closed out October at $6.94 and opened November at $7. The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.